Search Results for 'combination therapies'
-
Biologics, Proteins, Vaccines | Breaking News | Industry News
Gilead to Acquire Forty Seven for $4.9B
Will gain lead product candidate magrolimab in clinical development for the treatment of several cancers03.02.20
-
Realizing the Full Potential of Precision Medicine in Oncology
Innovation in oncology drug development is being driven by “precision medicine"Peter Larson, Executive Medical Director, Hematology-Oncology, Premier Research 01.28.20
-
APIs | Cytotoxics and High Potency Manufacturing | Facilities
Flamma Arrives in the U.S.
Italian CDMO sets down roots in the U.S. market with purchase of Teva facility.Tim Wright, Editor, Contract Pharma 10.15.19
-
Collaborations & Alliances | Drug Development
Bayer, BMS, Ono to Collaborate on Colorectal Cancer Treatments
Aims to evaluate the combination of Bayer's Stivarga and BMS / Ono's Opdivo in patients with MSS mCRC07.18.19
-
GENFIT, Terns Pharmaceuticals to Commercialize Elafibranor in China
For treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC)06.27.19
-
Drug Development
What I’m Looking Forward to at ASCO 2019
Erin Finot discusses the advances in science and oncology drug development at ASCOErin Finot, MS, MBA, Global Head of Immuno-Oncology, Oncology Division, IQVIA Biotech 05.28.19
-
Drug Development | Preclinical Outsourcing
New Drug Development Strategies Needed for Alzheimer’s Treatments
Selecting a single CRO partner that can take CNS compounds from functional screening in vitro through in vivo and beyondBirgit Hutter-Paier, Senior Director and Head of Neuropharmacology, QPS 05.10.19
-
Collaborations & Alliances | Drug Development
Boehringer, AMAL Enter Clinical Collaboration
Will evaluate ATP128 in combination with BI754091 in colorectal cancer05.02.19
-
APIs | Cytotoxics and High Potency Manufacturing
The Embedded CDMO
Pfizer CentreOne’s JoyL Silva talks about the advantages of being parked inside PfizerTim Wright, Editor, Contract Pharma 04.05.19
-
Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
Novartis, Pfizer Partner for NASH
A complex condition with no available treatment options, NASH affects up to 6.5% of the population worldwide10.29.18
-
Bio News | Breaking News | Drug Development | Drug Discovery | Industry News | Promotions & Moves | R&D
Aileron Therapeutics Names President & CEO
Manuel Aivado, MD, PhD has over 20 years experience, and has served as Aileron’s SVP, CMO, and CSO since 201209.06.18
-
Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Laboratory Testing | R&D
Harbour BioMed, Kelun-Biotech Enter Agreement
To develop & commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of Greater China08.21.18
-
-
-
Clinical Trials | Drug Development | Industry News | Information Technology
Ready for ASCO
Why ASCO’s annual meeting is one of the most important events in the oncology communityDr. Eric Groves, Vice President of Strategic Drug Development, R&D Solutions, IQVIA 06.01.18
-
Analytical Services | Bio News | Collaborations & Alliances | Industry News | R&D
Symcel, Karolinska Institutet Enter Partnership
For the evaluation of calScreener technology as an improved method to test for combinations of antibiotics in sepsis patients04.11.18
-
Bio News | Drug Development | Drug Discovery | Industry News | Methods Development | Reader Showcase
Crown Bioscience Launches CrownSyn
The tool aims to help researchers to understand drug combination effects01.12.18
-
cGMP Manufacture | Industry News
WuXi Biologics Licenses GLS-010 to Arcus Biosciences
WuXi Biologics will be the exclusive manufacturer for GLS-010 in the licensed territories08.17.17
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News
AstraZeneca, Merck in $8.5B Oncology Pact
Will co-develop and co-commercialize Lynparza for multiple cancer types08.03.17
-
-
-
Biologics, Proteins, Vaccines
Will Immunotherapy Knock Out Cancer?
Innovative immunotherapy companies discuss with WuXi AppTec what’s next for this rapidly developing field ahead of BIO 2017.Online Exclusives06.14.17
-
Collaborations & Alliances | Drug Development
Novartis, BMS in Opdivo Clinical Collaboration
To investigate Mekinist with Opdivo and Opdivo + Yervoy in metastatic colorectal cancer06.06.17
-
Analytical Services | Bioanalytical Services | R&D
CROs & Next-Gen Drug Development
R&D trends drive outsourcing in today’s marketKristin Brooks, Contract Pharma 05.09.17
-
Clinical Trial Materials | Clinical Trials | Drug Development | Industry News
Regeneron, SillaJen in Clinical and Supply Pact
To evaluate Regeneron's PD-1 inhibitor in combination with SillaJen's Pexa-Vec in kidney cancer05.08.17
-
Clinical Trials | Collaborations & Alliances | Drug Development
Corvus, Genentech Expand Clinical Collaboration
To evaluate CPI-444 in combination with Atezolizumab in non-small cell lung cancer05.02.17
-
Clinical Trials | Collaborations & Alliances | Drug Development
Lilly, Merck Expand Immuno-Oncology Alliance
Adds new study of LARTRUVO with KEYTRUDA in previously treated advanced or metastatic soft tissue sarcoma01.11.17
-
Drug Delivery | Drug Development
-
Breaking News | Industry News
Crown Bioscience Strengthens Immuno-oncology Capabilities
HuGEMM to assess the efficacy of human biologic therapeutics without mouse surrogates04.08.16
-
Analytical Services | Bioanalytical Services | Industry News
Smithers Avanza Expands Bioanalytical Services Division
Adds senior scientific and support personnel and new liquid handling robotics instrumentation03.09.16
-
Collaborations & Alliances | Drug Development | R&D
Peregrine Pharma and NCCN Form Clinical Collaboration
NCCN alliance includes 26 leading cancer centers01.06.16
-
Clinical Trials | Collaborations & Alliances | Drug Development | R&D
Lion Bio Enters Collab with MedImmune
Research to focus on novel immuno-oncology combination therapies12.21.15
-
Clinical Trials | Collaborations & Alliances | Drug Development
Lilly, AZ Expand Immuno-oncology Alliance
Will evaluate a range of additional combinations across their portfolios10.22.15
